À LA UNE de la Rhumatologie
-
Mutant IL-2-expressing mesenchymal stromal cells promote regulatory T cells proliferation and activation in collagen induced arthritis mice
Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by its deleterious effects on bone and cartilage within joints, leading to swelling, pain, and functional impairment[1]. Clinically, treatment involves the use of disease-modifying anti-rheumatic drugs (DMARDs), NSAIDs, glucocorticoids, and biologics; however, their prolonged use may result in a spectrum of adverse effects[2].... Lire la suite
Arthritis Research & Therapy 2025; 28(1):...
-
Concurrent seronegative spondyloarthropathy and Takayasu’s arteritis: a case report and literature review
Seronegative spondyloarthropathy (SpA) and Takayasu’s arteritis (TA) are distinct autoimmune disorders characterized by chronic inflammation. These conditions typically present as isolated entities and their coexistence is rare [1, 2–3]. Patients with concurrent SpA and TA often present with a more insidious onset and pronounced systemic inflammatory response compared to those with SpA... Lire la suite
Diagnostic Pathology 2025; 21(1): 5
-
Efficacy and safety of Janus kinase 1/2 inhibitor KL130008 in active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase II trial...
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic synovitis and progressive joint destruction that affects 0.5–1% of the global population, making it one of the leading causes of disability [1, 2]. Although biological and conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) substantially improve prognosis, they prove ineffective, intolerable or unsafe... Lire la suite
BMC Medicine 2025; 24(1): 27
-
Seropositive rheumatoid arthritis in osteogenesis imperfecta type XI (FKBP10 mutation): first case report and literature review
Osteogenesis imperfecta (OI) is a rare skeletal dysplasia that occurs in approximately 1 in every 15,000 to 20,000 individuals [1]. OI is a heterogeneous disorder primarily caused by mutations in genes involved in the production or processing of type I collagen and is characterized by bone fragility resulting in fractures, bone deformities, and growth retardation [2]. OI can also lead to extra-skeletal... Lire la suite
Orphanet Journal of Rare Diseases 2025; 21(1):...
- Consultez les archives
